131 related articles for article (PubMed ID: 9042266)
1. Combined use of urinary UGP and serum CA 125 in the diagnosis of gynecological cancers.
Plebani M; Navaglia F; Basso D; De Paoli M; Nicoletto MO; Maraglino E; Torre GC
Anticancer Res; 1996; 16(6B):3833-8. PubMed ID: 9042266
[TBL] [Abstract][Full Text] [Related]
2. Urinary gonadotropin peptide (UGP) and serum CA 125 in gynaecologic practice, a clinical prospective study.
Schutter EM; Mijatovic V; Kok A; Van Kamp GJ; Verstraeten R; Verheijen RH
Anticancer Res; 1999; 19(6C):5551-7. PubMed ID: 10697615
[TBL] [Abstract][Full Text] [Related]
3. Beta-core fragment (beta-core/UGF/UGP), a tumor marker: a 7-year report.
Cole LA; Tanaka A; Kim GS; Park SY; Koh MW; Schwartz PE; Chambers JT; Nam JH
Gynecol Oncol; 1996 Feb; 60(2):264-70. PubMed ID: 8631549
[TBL] [Abstract][Full Text] [Related]
4. Urinary gonadotropin peptide (UGP) as a marker of gynecologic malignancies.
Walker R; Crebbin V; Stern J; Scudder S; Schwartz P
Anticancer Res; 1994; 14(5A):1703-9. PubMed ID: 7847804
[TBL] [Abstract][Full Text] [Related]
5. UGP in urogenital disorders: Egyptian experience.
el-Ahmady O; Halim AB; Gad M; Walker R
Anticancer Res; 1996; 16(4B):2301-8. PubMed ID: 8694560
[TBL] [Abstract][Full Text] [Related]
6. UGP--a tumor marker of gynecologic and breast malignancies? Specificity and sensitivity in pretherapeutic patients and the influence of hormonal substitution on the expression of UGP.
Schwarz-Roeger U; Petzoldt B; Waldschmidt R; Walker RP; Bauknecht T; Kiechle M
Anticancer Res; 1997; 17(4B):3041-5. PubMed ID: 9329597
[TBL] [Abstract][Full Text] [Related]
7. Urinary gonadotropin peptide in patients with cancer of digestive organs.
Motoo Y; Watanabe H; Yamaguchi Y; Mouri I; Fujii T; Yamakawa O; Satomura Y; Okai T; Sawabu N
Anticancer Res; 1996; 16(4A):2041-8. PubMed ID: 8712740
[TBL] [Abstract][Full Text] [Related]
8. Urinary human chorionic gonadotropin free beta-subunit and beta-core fragment: a new marker of gynecological cancers.
Cole LA; Wang YX; Elliott M; Latif M; Chambers JT; Chambers SK; Schwartz PE
Cancer Res; 1988 Mar; 48(5):1356-60. PubMed ID: 3342414
[TBL] [Abstract][Full Text] [Related]
9. [Preliminary experience with a new tumor marker in obstetrics and gynecology: UGP (Urinary Gonadotropin Protein)].
Radici E; Persiani P; Stroppa S; Lombardi PL; Torre GC
Minerva Ginecol; 1996; 48(1-2):5-9. PubMed ID: 8750482
[TBL] [Abstract][Full Text] [Related]
10. Urinary gonadotropin peptide: collection of specimens and cutoff levels.
Plebani M; Navaglia F; Bacelle L; Polonio S; Lazzari F; Marchetti M
J Clin Lab Anal; 1995; 9(4):230-3. PubMed ID: 7562239
[TBL] [Abstract][Full Text] [Related]
11. Assessment of urinary gonadotropin in solid carcinomas other than gynecological tumors.
von Kleist S; Walker B; Walker R
J Clin Lab Anal; 1996; 10(4):184-92. PubMed ID: 8811461
[TBL] [Abstract][Full Text] [Related]
12. Urinary cyclic GMP after treatment of gynecological cancer. A prognostic marker of clinical outcome.
Orbo A; Hanevik M; Jaeger R; Van Heusden S; Sager G
Anticancer Res; 2007; 27(4C):2591-6. PubMed ID: 17695420
[TBL] [Abstract][Full Text] [Related]
13. Clinical applications of urinary gonadotropin peptides (UGP) in gynecologic oncology.
Schwartz PE; Cracchiolo BM; Cole LA
Anticancer Res; 1996; 16(4B):2135-9. PubMed ID: 8694533
[TBL] [Abstract][Full Text] [Related]
14. [Development of highly sensitive enzyme immunoassay to measure urinary beta-core fragment in patients with gynecological cancer].
Nishimura R; Kobayashi K; Katsuno M; Kobayashi T
Nihon Sanka Fujinka Gakkai Zasshi; 1990 Feb; 42(2):143-8. PubMed ID: 1690253
[TBL] [Abstract][Full Text] [Related]
15. [Human chorionic gonadotropin beta-core fragment (hCGbetacf)].
Okamoto T
Nihon Rinsho; 2005 Aug; 63 Suppl 8():765-7. PubMed ID: 16149635
[No Abstract] [Full Text] [Related]
16. Chronobiologic aspects of urinary gonadotropin peptide (UGP).
Cornélissen G; Halberg F; Walker R; Zaslavskaya RM; Fine RL; Haus E
In Vivo; 1995; 9(4):359-62. PubMed ID: 8555435
[TBL] [Abstract][Full Text] [Related]
17. A diagnostic evaluation of serum human telomerase reverse transcriptase mRNA as a novel tumor marker for gynecologic malignancies.
Miura N; Kanamori Y; Takahashi M; Sato R; Tsukamoto T; Takahashi S; Harada T; Sano A; Shomori K; Harada T; Kigawa J; Ito H; Terakawa N; Hasegawa J; Shiota G
Oncol Rep; 2007 Mar; 17(3):541-8. PubMed ID: 17273731
[TBL] [Abstract][Full Text] [Related]
18. TATI (tumor associated trypsin inhibitor) and cancer antigen 125 (CA 125) in patients with early-stage endometrial cancer.
Peters-Engl C; Buxbaum P; Ogris E; Sevelda P; Medl M
Anticancer Res; 1998; 18(6B):4635-9. PubMed ID: 9891532
[TBL] [Abstract][Full Text] [Related]
19. Preoperative determination of CASA (Cancer Associated Serum Antigen) and CA-125 for the discrimination between benign and malignant pelvic tumor mass: a prospective study.
Sehouli J; Akdogan Z; Heinze T; Könsgen D; Stengel D; Mustea A; Lichtenegger W
Anticancer Res; 2003; 23(2A):1115-8. PubMed ID: 12820357
[TBL] [Abstract][Full Text] [Related]
20. The role of serum tetranectin, CA 125, and a combined index as tumor markers in women with pelvic tumors.
Høgdall CK; Mogensen O; Tabor A; Mogensen B; Jakobsen AK; Nørgaard-Pedersen B; Larsen SO; Clemmensen I
Gynecol Oncol; 1995 Jan; 56(1):22-8. PubMed ID: 7821842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]